LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Erasca Inc

Fechado

1.4 -3.45

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.37

Máximo

1.41

Indicadores-chave

By Trading Economics

Rendimento

1.3M

-31M

EPS

-0.11

Funcionários

103

EBITDA

-750K

-36M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+203.45% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-48M

346M

Abertura anterior

4.85

Fecho anterior

1.4

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Erasca Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mai. de 2025, 10:30 UTC

Principais Notícias

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 de mai. de 2025, 06:30 UTC

Ganhos

5 Things We've Learned From Retail Earnings -- Barrons.com

31 de mai. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

30 de mai. de 2025, 23:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 de mai. de 2025, 21:30 UTC

Principais Notícias

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 de mai. de 2025, 21:15 UTC

Principais Notícias

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 de mai. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

30 de mai. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 de mai. de 2025, 20:24 UTC

Principais Notícias

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 de mai. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

30 de mai. de 2025, 19:44 UTC

Conversa de Mercado

Gold Breaks 4-Month Winning Streak -- Market Talk

30 de mai. de 2025, 19:38 UTC

Conversa de Mercado

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 de mai. de 2025, 19:29 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 de mai. de 2025, 19:14 UTC

Conversa de Mercado

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 de mai. de 2025, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 de mai. de 2025, 18:51 UTC

Conversa de Mercado

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 de mai. de 2025, 18:37 UTC

Conversa de Mercado
Ganhos

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 de mai. de 2025, 18:04 UTC

Principais Notícias

S&P 500 Falls After More Trump-China Friction -- WSJ

30 de mai. de 2025, 17:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mai. de 2025, 17:47 UTC

Conversa de Mercado

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 de mai. de 2025, 17:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 de mai. de 2025, 17:38 UTC

Conversa de Mercado

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 de mai. de 2025, 17:31 UTC

Conversa de Mercado

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 de mai. de 2025, 17:14 UTC

Principais Notícias

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 de mai. de 2025, 16:31 UTC

Ganhos

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 de mai. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

30 de mai. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

30 de mai. de 2025, 16:16 UTC

Principais Notícias

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 de mai. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

30 de mai. de 2025, 16:14 UTC

Principais Notícias

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Comparação entre Pares

Variação de preço

Erasca Inc Previsão

Preço-alvo

By TipRanks

203.45% parte superior

Previsão para 12 meses

Média 4.4 USD  203.45%

Máximo 6 USD

Mínimo 3 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Erasca Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.39 / 1.44Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Very Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.